新地(00016.HK)雷霆:「匯璽III」將推出3號價單涉293伙
新地(00016.HK)副董事總經理雷霆在發布會上表示,昨日推售的西南九龍「匯璽III」首輪352伙單位已近乎沽清,將會即日推出3號價單,涉及293伙,大部分以原價加推,只有少部分是輕微加價1至2%。他解釋,這批單位的售價較首兩張價單為高,主要是由於多屬高層及海景單位,會盡快公布銷售安排。
至於昨日的買家分布有兩成是來自港島,48%來自九龍,32%來自新界,看到一房及四房單位較受歡迎。而3號價單將會多推一些四房單位。
他表示,最近外圍因素令股市表現波動,因此選擇買樓保值的人增加,加上聯儲局宣布減息,亦會加大一些租樓的人的買樓意欲,看到最近銷情不錯,希望社會亦能夠盡快回復平靜。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.